SNY

Sanofi ADR

SNY, USA

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

https://www.sanofi.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SNY
stock
SNY

Price-Driven Insight from (SNY) for Rule-Based Strategy Stock Traders Daily

Read more →
SNY
stock
SNY

The Truth About Sanofi S.A.: Is This Pharma Giant the Sleeper Stock Everyone’s Sleeping On? AD HOC NEWS

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$58.6844

Analyst Picks

Strong Buy

5

Buy

3

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

15.69

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Low

1.57

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

3.82 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.16 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

28.47 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Low

0.77

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 11.55% of the total shares of Sanofi ADR

1.

Dodge & Cox

(2.9417%)

since

2025/06/30

2.

Dodge & Cox Stock I

(2.2614%)

since

2025/06/30

3.

Fisher Asset Management, LLC

(0.5388%)

since

2025/06/30

4.

Bank of America Corp

(0.4101%)

since

2025/06/30

5.

Amvescap Plc.

(0.3769%)

since

2025/06/30

6.

Capital World Investors

(0.3427%)

since

2025/06/30

7.

Morgan Stanley - Brokerage Accounts

(0.3387%)

since

2025/06/30

8.

American Funds Washington Mutual A

(0.3175%)

since

2025/06/30

9.

Capital Group Wash Mutual Invtrs Comp

(0.3175%)

since

2025/06/30

10.

Barrow Hanley Mewhinney & Strauss LLC

(0.2986%)

since

2025/06/30

11.

T. Rowe Price Associates, Inc.

(0.2266%)

since

2025/06/30

12.

BlackRock Inc

(0.2243%)

since

2025/06/30

13.

Wellington Management Company LLP

(0.1776%)

since

2025/06/30

14.

Franklin Resources Inc

(0.1753%)

since

2025/06/30

15.

Boston Partners Global Investors, Inc

(0.1636%)

since

2025/06/30

16.

Vanguard Windsor Investor Shares

(0.1623%)

since

2025/06/30

17.

Federated Hermes Inc

(0.1595%)

since

2025/06/30

18.

Invesco Comstock A

(0.1501%)

since

2025/07/31

19.

Invesco Large Cap Value

(0.149%)

since

2025/06/30

20.

FMR Inc

(0.1478%)

since

2025/06/30

21.

Mondrian Investment Partners Ltd

(0.1412%)

since

2025/03/31

22.

Envestnet Asset Management Inc

(0.1409%)

since

2025/06/30

23.

Royal Bank of Canada

(0.1328%)

since

2025/06/30

24.

Nuveen, LLC

(0.127%)

since

2025/06/30

25.

Dodge & Cox Balanced I

(0.1151%)

since

2025/06/30

26.

Dodge & Cox Balanced Composite

(0.1151%)

since

2025/06/30

27.

Wells Fargo & Co

(0.1144%)

since

2025/06/30

28.

Natixis Advisors, LLC.

(0.1143%)

since

2025/06/30

29.

Robeco BP US Premium Equities IH €

(0.0878%)

since

2025/07/31

30.

Bridge Builder Large Cap Value

(0.0753%)

since

2025/08/31

31.

Putnam Focused Large Cap Value ETF

(0.0685%)

since

2025/07/31

32.

T. Rowe Price Health Sciences

(0.0546%)

since

2025/07/31

33.

Vanguard Windsorâ„¢ II Inv

(0.0542%)

since

2025/06/30

34.

Nicholas Multi-Cap Growth Equity

(0.0515%)

since

2025/06/30

35.

Nicholas

(0.0515%)

since

2025/06/30

36.

Mondrian Intl Equity Value Delivered

(0.0509%)

since

2025/06/30

37.

CREF Stock R3

(0.0492%)

since

2025/07/31

38.

American Century Equity Income Inv

(0.0427%)

since

2025/06/30

39.

American Century US Value Yield Eq Tr 1

(0.0427%)

since

2025/06/30

40.

Nuveen Large Cap Value Retire

(0.0413%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.8306

Latest Release

Date

2025-09-30

EPS Actual

1.6889

EPS Estimate

1.62

EPS Difference

0.0689

Surprise Percent

4.2531%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.3)
GARP
Fair GARP(5)
Growth
Moderate Growth(4.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.